TY - JOUR
T1 - The prognostic value of baseline EARL standardized FDG PET indices in pediatric and adolescent high-grade osteosarcoma
AU - van Ewijk, Roelof
AU - Dandis, Rana
AU - Rodewijk, Janna
AU - de Keizer, Bart
AU - ter Horst, Simone A.J.
AU - van de Sande, Michiel A.J.
AU - van der Heijden, Lizz
AU - Merks, Johannes H.M.
AU - Haveman, Lianne M.
AU - Braat, Arthur J.A.T.
N1 - © 2025. The Author(s).
PY - 2025/1
Y1 - 2025/1
N2 - Objective: To investigate the prognostic value of baseline European Association of Nuclear Medicine Research Ltd. (EARL) standardized [18F]fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG PET-CT) quantitative values for survival and to evaluate cutoff values identified in other studies. Materials and methods: Pediatric and adolescent patients with high-grade osteosarcoma were included. Baseline [18F]FDG PET-CT, with EARL-accredited reconstructions, was the standard diagnostic staging procedure. Cox proportional hazard analysis for event-free survival (EFS) and overall survival (OS) was performed with clinical prognostic factors. Kaplan–Meier analysis and log-rank tests were applied to investigate the prognostic performance of the [18F]FDG PET indices. Results: In total, 66 patients were included in this study. In the univariable Cox regression analysis, peak lean-body mass corrected SUV (SULpeak) (hazard ratio (HR): 1.04), total lesion glycolysis (TLG) (HR: 1.0), and metabolic tumor volume (MTV) (HR: 1.0) were not associated with EFS or OS. Log-rank analysis showed a significant difference in EFS for all SULmax and SULpeak cutoffs. For MTVtotal the maximum Youden, and for TLGtotal, the maximum Youden and maximally selected rank cutoff resulted in a significant EFS difference. No cutoff for any measure showed a significant difference in OS between the groups. ROC curves for event status had an AUC of 0.67, 0.66, 0.64, and 0.64 for SULmax, SULpeak, MTVtotal, and TLGtotal, respectively. Conclusion: In this study, the baseline EARL-standardized [18F]FDG PET indices of children and adolescents with osteosarcoma were not prognostic of EFS or OS. The proposed prognostic cutoffs from earlier studies suffer from important technical and statistical issues. Key Points: Question Prognostic value of baseline [18F]FDG PET-CT imaging markers have been reported for histologic response and survival in high-grade osteosarcoma but have not been validated for clinical practice. Findings Baseline SUVpeak, TLGtotal, and MTVtotalmeasured on EARL-accredited reconstructions were not prognostic factors for survival in pediatric and adolescent patients with high-grade osteosarcoma. Clinical relevance A wide range of values for SUVpeakand SUVmaxcutoffs with similar prognostic value were identified, questioning the value of a single proposed cutoff. Lack of validation, with important technical and statistical issues of proposed prognostic cutoffs, limits clinical implementation.
AB - Objective: To investigate the prognostic value of baseline European Association of Nuclear Medicine Research Ltd. (EARL) standardized [18F]fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG PET-CT) quantitative values for survival and to evaluate cutoff values identified in other studies. Materials and methods: Pediatric and adolescent patients with high-grade osteosarcoma were included. Baseline [18F]FDG PET-CT, with EARL-accredited reconstructions, was the standard diagnostic staging procedure. Cox proportional hazard analysis for event-free survival (EFS) and overall survival (OS) was performed with clinical prognostic factors. Kaplan–Meier analysis and log-rank tests were applied to investigate the prognostic performance of the [18F]FDG PET indices. Results: In total, 66 patients were included in this study. In the univariable Cox regression analysis, peak lean-body mass corrected SUV (SULpeak) (hazard ratio (HR): 1.04), total lesion glycolysis (TLG) (HR: 1.0), and metabolic tumor volume (MTV) (HR: 1.0) were not associated with EFS or OS. Log-rank analysis showed a significant difference in EFS for all SULmax and SULpeak cutoffs. For MTVtotal the maximum Youden, and for TLGtotal, the maximum Youden and maximally selected rank cutoff resulted in a significant EFS difference. No cutoff for any measure showed a significant difference in OS between the groups. ROC curves for event status had an AUC of 0.67, 0.66, 0.64, and 0.64 for SULmax, SULpeak, MTVtotal, and TLGtotal, respectively. Conclusion: In this study, the baseline EARL-standardized [18F]FDG PET indices of children and adolescents with osteosarcoma were not prognostic of EFS or OS. The proposed prognostic cutoffs from earlier studies suffer from important technical and statistical issues. Key Points: Question Prognostic value of baseline [18F]FDG PET-CT imaging markers have been reported for histologic response and survival in high-grade osteosarcoma but have not been validated for clinical practice. Findings Baseline SUVpeak, TLGtotal, and MTVtotalmeasured on EARL-accredited reconstructions were not prognostic factors for survival in pediatric and adolescent patients with high-grade osteosarcoma. Clinical relevance A wide range of values for SUVpeakand SUVmaxcutoffs with similar prognostic value were identified, questioning the value of a single proposed cutoff. Lack of validation, with important technical and statistical issues of proposed prognostic cutoffs, limits clinical implementation.
KW - Osteosarcoma
KW - PET-CT
KW - Pediatrics
KW - Prognostic factors
KW - Quality control
KW - Prognosis
KW - Humans
KW - Male
KW - Osteosarcoma/diagnostic imaging
KW - Neoplasm Grading
KW - Bone Neoplasms/diagnostic imaging
KW - Adolescent
KW - Female
KW - Fluorodeoxyglucose F18
KW - Retrospective Studies
KW - Positron Emission Tomography Computed Tomography/methods
KW - Radiopharmaceuticals
KW - Child
UR - https://www.scopus.com/pages/publications/85217238795
UR - https://www.mendeley.com/catalogue/1ad01bf3-0a0b-30df-b366-985b0b0d5ba1/
U2 - 10.1007/s00330-025-11372-z
DO - 10.1007/s00330-025-11372-z
M3 - Article
C2 - 39853333
AN - SCOPUS:85217238795
SN - 0938-7994
VL - 35
SP - 4233
EP - 4242
JO - European Radiology
JF - European Radiology
IS - 7
ER -